Overview

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Antibodies, Monoclonal